According to a new study published in Nature Genetics, scientists have discovered seven new subtypes of ovarian cancer.
The subtypes note an important progression as scientists and doctors are able to determine the processes in the development of rare cancers and utilise the findings to develop drug therapies. Current standard therapies include debulking surgery and platinum-based chemotherapy.
This discovery of subtypes is important because most women with rare cancers do not respond to chemotherapy well. This saves the patient unnecessary chemotherapy and provides an opportunity to create distinct therapeutic solutions customised to the patient’s needs.
Research progress, coupled with the releases of new innovative drugs, will create a dynamic environment to provide enhanced therapeutic solutions for patients. GlobalData's analysts have identified numerous pipeline products expected to be launched in 2017. With these new drugs, the mature market will begin to diversify and create new therapeutic solutions for patients burdened with rare forms of ovarian cancer.